Even though differences in health outcomes between Black and white people are well-established, a small survey finds that patients' race is not routinely mentioned atop their electronic medical record. The survey looked at data from 1,200 patients, and checked for race in the first line of the EMR […]
Drugmakers Raise Prices 3.3% in the New Year
This month pharmaceutical companies have increased list prices on hundreds of branded drugs -- mostly between 2-7% (with only a couple companies daring the optics of double-digit hikes). In aggregate, however, the rate of increase across a market basket of the most common branded therapies was lower […]
ICER Identifies Most Significant 2019 US Drug-Price Hikes
The Institute for Clinical and Economic Review (ICER) today published its latest report on Unsupported Price Increases (UPI) of prescription drugs in the United States. Among the top drugs with price increases in 2019 that had substantial effects on US spending, ICER determined that seven of 10 […]
EQRx Scales Disruptive Model of Important New Medicines
EQRx, a company committed to developing and delivering important new medicines at lower prices, today announced that it has raised $500 million in Series B financing. Since launching a year ago, EQRx has raised approximately $750 million to advance its mission of bringing new medicines to treat […]
[On-demand Webinar] Avalere 2021 Healthcare Industry Outlook
The accelerated changes and increased uncertainties in healthcare brought on by the COVID-19 pandemic will continue into 2021, and its impacts are likely to shape healthcare for years to come. While prevalent uncertainty is a given, the broad outline of a new era is already emerging. More than ever, […]
Fishawack Health Acquires The Hive Health Group
Fishawack Health (Fishawack) is a leading global commercialization partner for the modern life sciences era. The company’s three core operating units—Commercial, Consulting, and Medical Communications—can be leveraged individually but are designed for dynamic collaboration, with expert teams […]
Virtual ISPOR 2021 Abstracts Due & Reviewers Needed!
Virtual ISPOR 2021 offers you an opportunity to present your research virtually to the leading global conference for health economics and outcomes research. Submit today and contribute to the future of HEOR and the difference it is making in today’s global healthcare landscape. New This Year: […]
The 5 Numbers That Will Define Healthcare Value in 2021
Real world studies of COVID-19’s impact on health care utilization are arriving daily and their continued publication throughout the next year will be the defining characteristic of HEOR in 2021. One systematic review (in preprint) has already reported on 81 such studies. In these studies, which […]
Seniors Face Crushing Drug Costs as Congress Stalls on Capping Medicare Out-Of-Pockets
Unlike private health insurance, Medicare Part D drug plans have no cap on patients’ 5% coinsurance costs once they hit $6,550 in drug spending this year (up from $6,350 in 2020), except for very low-income beneficiaries. President-elect Biden favors a cap, and Democrats and Republicans in Congress […]
Read Up On How Regulators Are Using RWE
RWE is playing a growing role in FDA approvals. According to an Aetion analysis, 49 percent of submissions for new drugs and biologics in 2019 included an RWE study. In 2020, that figure jumped to 75 percent. In Aetion’s growing library of FDA Decision Alerts, they share examples in which RWE was […]
The Bane of Prior Authorization
In a STAT op-ed, Brian Barnett, a psychiatrist at the Cleveland Clinic, discusses the burden of completing prior authorizations to ensure patients can retain access to medications. While prior authorizations can be used to ethically and efficiently steer patients toward lower-cost, clinically […]
Has COVID-19 Changed Prescription Drug Pricing Forever?
As the COVID-19 pandemic continues to disrupt our lives and health care system on a historic scale, it is worth considering whether it has also revolutionized drug development and pricing in a profound way. COVID-19 vaccines were produced in record time using a novel approach: Drug makers committed […]
ICER To Release Final Assessment of Selected High-impact Drugs
ICER will be reviewing changes in the evidence base for each of these drugs and assess whether or not new clinical data exists that could suggest that the drugs could be significantly more beneficial for patients than what was previously understood. ICER published the final draft of its first UPI […]
Enjoy AMCP Learn Programs Available to You
AMCP Learn provides numerous on-demand CPE programs that will help you with your goals. Enjoy programs like Navigating Changes in Clostridioides difficile Prevention and Treatment, Value-based Contracting, Fundamentals of Managed Care Pharmacy Certificate Programs, and more! […]
Volunteer with AMCP Foundation
Give the gift of time by volunteering. The AMCP Foundation has opportunities for you to donate your time. Volunteering is a great way to be hands-on as you help fulfill our mission of research and education. Become a volunteer today! AMCP Foundation P&T Competition Judges(Apply by Jan. 17, […]
The AMCP Podcast Powered by PopHealth Week Launches Next Week
AMCP is proud to partner with renowned health care experts Fred Goldstein and Gregg Masters from PopHealth Week to launch a podcast that fosters conversation about the biggest challenges facing managed care pharmacy and up-to-the minute hot topics. They are shining the spotlight on leading voices […]
Panalgo’s IHD Platform to Be Used by the EU Medicines Agency for Real-World Data Analytics
Panalgo, a leading healthcare analytics company, today announced that its Instant Health Data (IHD) platform will be used by the European Medicines Agency (EMA) to facilitate the analysis of real-world data. EMA will use IHD to undertake rapid analyses of Electronic Healthcare Data (EHDs) […]
Tracing the Health Care Experience Informs Decision-making
Mapping the patient journey is a worthwhile exercise to undertake because it answers critical questions of interest to all health care stakeholders. The richness of patient journey mapping can help develop patient cohorts and assess effectiveness of therapeutics. Total health care utilization and […]
Why Population Health Isn’t the ‘Virtuous’ Approach
Mark Ganz isn't a fan of healthcare's fixation on population health. Ganz, who recently left the role of CEO of Cambia Health Solutions, told Fierce Healthcare in a recent interview that looking at health through a population lens creates distance between the healthcare system and the patient […]
Driving More Value and Cost Savings With SDOH Data
Getting a Social Determinant of Health (SDOH) initiative off the ground requires thoughtful coordination and analysis between analytics teams, clinicians, social workers and others, and buy-in from leadership. SDOH data includes details about income, education, race, gender and other social factors. […]
ICER Seeks Applications for New Health Technology Assessment Fellowship
The Institute for Clinical and Economic Review (ICER) is now accepting applications for the inaugural cycle of a new Health Technology Assessment (HTA) Fellowship. The ICER HTA Fellowship is a paid full-time one-year program for post-master's and post-doctoral graduates that provides experiential […]
RxSense Joins with Hy-Vee to Launch New PBM Vivid Clear Rx
RxSense was founded in 2015 with a singular focus on developing technology solutions that improve healthcare transparency and access to more affordable medications. RxSense also utilizes its advanced platform and direct contracts with the nation’s largest pharmacies (including CVS, Walmart and […]
Healthcare Venture Launched by Amazon, JPMorgan and Berkshire Hathaway Goes Bust
Haven—the healthcare company formed by Amazon, JPMorgan Chase and Berkshire Hathaway—is apparently no more. The healthcare company began telling employees on Monday about plans to shut down by the end of next month, CNBC reported first on Monday morning. Haven was first announced in January 2018 as […]
Hospitals Lose Another Attempt to Stave Off Price Transparency
A federal appeals court ruled against hospitals' efforts to stop regulators from forcing them to reveal the secret negotiated prices they reach with insurers, according to an opinion filed Tuesday. Hospitals were hoping for intervention from the D.C. Circuit Court of Appeals as the rule requires […]
How Does Cost-Sharing Impact Spending Growth and Cost-Effective Treatments?
The growth of health care spending has been a longstanding policy concern. Over the years, several innovations have been proposed to lower levels of health care spending; however, their impact has been limited and not sustained over time. Costly new technology, while often an improvement to existing […]
Impact of the Pandemic on Medical and Scientific Affairs
In the latest episode of Impetus Digital's Fireside Chat, Dr. Shurjeel Choudhri, SVP and Head, Medical and Scientific Affairs, Bayer Canada, joins me for a wide-ranging conversation on several hot topics in Pharma and healthcare. Among many other things, we explore innovative digital technologies, […]
The Medical Science Liaison-DISC Personality Types Survey
The MSL role is constantly evolving and facing new challenges. MSLs are both scientific experts and relationship managers. As such, they are required to perform tasks that are extremely analytical and technical in nature, while being able to skilfully handle relationships on a human level. Each of […]
Trends That Matter for COVID Vaccine Distribution
As details continue to emerge about the availability of COVID-19 vaccines and how they will be administered, the role that payers will play in the process is becoming clearer, AIS Health reported. It's imperative for health plans to do two key things at the same time, according to Katherine […]
Drug Wholesale Prices Impact Payer Spending, Out-of-pocket Costs
Increases in drug wholesale list prices have a trickle-down effect that negatively impacts patient financial responsibility, such as out-of-pocket costs, and payer spending, according to a study published in JAMA Network Open. In recent years, the pharmaceutical industry has been scrutinized for […]
Use of Real-world Evidence in Economic Assessments of Pharmaceuticals in the US
In a recent study, investigators from the University of Washington School of Pharmacy reviewed cost-effectiveness and budget impact analyses in final evidence reports of pharmaceuticals published by ICER, calculating total number of RWE uses and the proportion of model inputs informed by RWE per […]
